ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.980,52
-0,15%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Wave Life Sciences Ltd (WVE)

  7. Wave Life Sciences Ltd (WVE) News

WVE

Wave Life Sciences (WVE)

Wave Life Sciences Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:WVE
DatumZeitQuelleÜberschriftSymbolFirma
10/05/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:WVEWave Life Sciences Ltd
09/05/202413h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
09/05/202413h30GlobeNewswire Inc.Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:WVEWave Life Sciences Ltd
09/05/202413h00GlobeNewswire Inc.Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific OfficerNASDAQ:WVEWave Life Sciences Ltd
07/05/202414h30GlobeNewswire Inc.Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:WVEWave Life Sciences Ltd
02/05/202414h30GlobeNewswire Inc.Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024NASDAQ:WVEWave Life Sciences Ltd
30/04/202414h30GlobeNewswire Inc.Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:WVEWave Life Sciences Ltd
23/04/202414h30GlobeNewswire Inc.Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA EditingNASDAQ:WVEWave Life Sciences Ltd
27/03/202413h30GlobeNewswire Inc.Wave Life Sciences to Present at Upcoming Investor ConferencesNASDAQ:WVEWave Life Sciences Ltd
06/03/202413h55Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:WVEWave Life Sciences Ltd
06/03/202413h39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
06/03/202413h30GlobeNewswire Inc.Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:WVEWave Life Sciences Ltd
28/02/202414h30GlobeNewswire Inc.Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024NASDAQ:WVEWave Life Sciences Ltd
27/02/202414h30GlobeNewswire Inc.Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular DystrophyNASDAQ:WVEWave Life Sciences Ltd
12/02/202422h15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:WVEWave Life Sciences Ltd
08/02/202401h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WVEWave Life Sciences Ltd
08/02/202401h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WVEWave Life Sciences Ltd
08/02/202401h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WVEWave Life Sciences Ltd
08/02/202401h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WVEWave Life Sciences Ltd
08/01/202414h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
08/01/202414h00GlobeNewswire Inc.Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 MilestonesNASDAQ:WVEWave Life Sciences Ltd
04/01/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
03/01/202414h30GlobeNewswire Inc.Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:WVEWave Life Sciences Ltd
15/12/202314h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
15/12/202314h30GlobeNewswire Inc.Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular DystrophyNASDAQ:WVEWave Life Sciences Ltd
08/12/202312h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WVEWave Life Sciences Ltd
08/12/202303h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
07/12/202313h00GlobeNewswire Inc.Wave Life Sciences Prices $100 Million Public Offering of Ordinary SharesNASDAQ:WVEWave Life Sciences Ltd
06/12/202322h13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WVEWave Life Sciences Ltd
06/12/202322h10GlobeNewswire Inc.Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:WVEWave Life Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:WVE

Kürzlich von Ihnen besucht

BOV
MDNE3F
MOURA DUBEAUX ON
BIT
P20VT7
NLBNPIT20VT7 20241220 50
BIT
P1V3C6
NLBNPIT1V3C6 20351221 15...
BIT
P1XE58
NLBNPIT1XE58 20240621 24
GATE
DYDXUSD
dYdX
EU
SGEID
Euronext G Eni SPA 01062...
NASDAQ
BIRD
Allbirds
USOTC
SLLTD
Recharge Resources (PK)
BIT
F18492
Vontobel Financial Produ...
USOTC
AHIX
Aluf (PK)
BIT
P1X4R0
NLBNPIT1X4R0 20991231 89...
BFNX
BGBUSD
BitgetToken
COIN
TROLLBTC
BIT
P20SO4
NLBNPIT20SO4 20240920 170
BIT
P207K5
NLBNPIT207K5 20991231 3....
NASDAQ
COLL
Collegium Pharmaceutical
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten